Two deaths reported in Japan in patients receiving liraglutide
This article was originally published in Scrip
Novo Nordisk has informed the regulatory authorities and medical professionals in Japan of the deaths of two patients who had been administered the company's novel antidiabetic Victoza (liraglutide).
You may also be interested in...
Singapore- and US-based rational antibody design venture closes major new financing to support progress of its novel pipeline, with its two lead assets set to enter the clinic shortly. CEO Piers Ingram talks to Scrip about plans and strategy.
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
European industry federation says first practical application of Japan’s cost effectiveness assessment system has highlighted a number of problems for both the scheme and its members, and calls for changes.